[ad_1]
The latest study, published in the New England Journal of Medicine, confirmed Thursday that the COVID-19 vaccine, developed by Pfizer Inc and BioNTech SE, is 95% average effective in preventing coronavirus disease.
Based on the results of clinical trials involving 43,548 people, the efficacy of the vaccine ranged from 90.3% to 97.6% in all subgroups. Although the vaccine is considered safe to use, the study noted that “short-term, mild to moderate pain, fatigue, and headache at the injection site may occur after administration.”
The Pfizer Inc./BioNTech vaccine applicant has already been approved for use by regulators in the UK, Canada and Saudi Arabia.
The United States Food and Drug Administration is also expected to announce its decision on the emergency use of this COVID vaccine later today.
United States
[ad_2]
